AWAKENINGNCT07907783
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Notable Recruitment opened
- Trial sites expanded: 0 → 6 locations
- Start date: Nov 2026 to Nov 10, 2026
- Minor Secondary endpoints: details revised at 2 of 5 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from baseline in non-vellus target area hair count
Timeframe: Week 24
Secondary (3)
Change from baseline in the Participant Assessment of Scalp Coverage
≥20% increase from baseline in non-vellus target area hair count
Change from baseline in non-vellus target area hair count
Arms and interventions
PP405 0.05% Topical GelExperimental
PP405 applied to the scalp from Day 1 to Week 24
Vehicle Topical GelPlacebo comparator
Vehicle applied to the scalp from Day 1 to Week 24
Drugs: PP405 0.05% Topical Gel, Vehicle Topical Gel
Sites
6 sites in 1 country